🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,387 results for “Le” Clear

  1. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, Placebo

    AstraZeneca AB

    Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection.

    phase 3 small molecule active

    1 trial

  2. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, placebo capsule G065, placebo capsule G040, JNJ-61186372, JNJ-73841937, JNJ-73841937-ZCY Placebo Oral Film-Coated Tablet

    Janssen-Cilag International N.V.

    EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  3. TAK-536TCH tablet

    Takeda

    Essential Hypertension

    phase 3 small molecule completed

    1 trial

  4. TAK-625

    Takeda

    Alagille Syndrome (ALGS)

    phase 3 small molecule completed

    1 trial

  5. TAK-625

    Takeda

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    phase 3 small molecule completed

    1 trial

  6. TAK-861

    Takeda

    Narcolepsy Type 1

    phase 3 small molecule active

    4 trials

  7. TAK-861

    Takeda

    Narcolepsy Type 1 (NT1)

    phase 3 small molecule active

    1 trial

  8. TAK-861, TAK-861 placebo (same excipients as TAK-861)

    Takeda

    Narcolepsy with Cataplexy (Narcolepsy Type 1)

    phase 3 small molecule active

    1 trial

  9. TAK-861, TAK-861 placebo (same excipients as TAK-861), TAK-861

    Takeda

    Narcolepsy with Cataplexy (Narcolepsy Type 1)

    phase 3 small molecule active

    1 trial

  10. TAK-861, TAK-861 placebo (same excipients as TAK-861), TAK-861

    Takeda

    Narcolepsy with Cataplexy (Narcolepsy Type 1)

    phase 3 small molecule active

    1 trial

  11. TALAZOPARIB, TALAZOPARIB, TALAZOPARIB, Xtandi - 40 mg soft capsules, TALAZOPARIB

    Pfizer Australia Pty Ltd

    Metastatic Castration-resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  12. TAMOXIFEN , EXEMESTANE , ANASTROZOLE , LETROZOLE , Verzenios 50 mg film-coated tablets

    Eli Lilly Co.

    Breast Cancer

    phase 3 small molecule active

    1 trial

  13. TAMOXIFEN, LETROZOLE, ANASTROZOLE, FULVESTRANT, LEUPRORELIN, OXYBUTYNIN, GOSERELIN, VENLAFAXINE, LEUPRORELIN, GOSERELIN, EXEMESTANE, VENLAFAXINE

    Shanghai Reinovax Biologics Co.,LTD

    Breast cancer

    phase 3 small molecule active

    1 trial

  14. TASIMELTEON, HETLIOZ 20 mg hard capsules

    Lacuna Pharma Pty Ltd

    Non-24 Hour Sleep-Wake Disorder

    phase 3 small molecule active

    1 trial

  15. TECFIDERA

    Biogen

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  16. TENOFOVIR DISOPROXIL , ENTECAVIR , VAY736, -, Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe, TENOFOVIR ALAFENAMIDE

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  17. TENOFOVIR DISOPROXIL AND EMTRICITABINE , Sunlenca 300 mg film-coated tablets, Sunlenca 464 mg solution for injection

    Gilead Sciences Pty Limited

    Human Immunodeficiency Virus (HIV-1) infection

    phase 3 small molecule active

    1 trial

  18. TERIFLUNOMIDE, INTERFERON BETA-1A, DIROXIMEL FUMARATE, INTERFERON BETA-1A, INTERFERON BETA-1A, GLATIRAMER ACETATE, Betaferon 250 microgram/ml, powder and solvent for solution for injection, OFATUMUMAB, GLATIRAMER ACETATE, DIMETHYL FUMARATE, PEGINTERFERON BETA-1A, DIMETHYL FUMARATE

    Novartis Pharmaceuticals

    relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  19. TIRBANIBULIN, Placebo of the new presentation of 350 mg/sachet drug product (hereafter referred as vehicle) is a smooth, creamy white to off-white ointment free from foreign particles, packed intact and properly sealed containing the same qualitative composition as the active product but without the active substance. The vehicle will be provided in a single-use packets to contain 350 mg of drug product., Klisyri 10 mg/g ointment

    Almirall, S.A.

    Actinic Keratosis on the Face or Scalp

    phase 3 small molecule active

    1 trial

  20. TNK-tPA

    The First People's Hospital of Lianyungang

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  21. TNX-102 SL Tablet 2.8 mg

    Tonix Pharmaceuticals Holding

    Primary Fibromyalgia

    phase 3 small molecule completed

    1 trial

  22. TNX-102 SL Tablet, 2.8 mg

    Tonix Pharmaceuticals Holding

    Fibromyalgia

    phase 3 small molecule terminated

    1 trial

  23. TNX-102 SL Tablet, 2.8mg

    Tonix Pharmaceuticals Holding

    Fibromyalgia

    phase 3 small molecule completed

    1 trial

  24. TNX-102 SL Tablet, 5.6 mg

    Tonix Pharmaceuticals Holding

    Fibromyalgia

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources